Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 9, 5, 1, 25 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myasthenia Gravis - Overview
Myasthenia Gravis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myasthenia Gravis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myasthenia Gravis - Companies Involved in Therapeutics Development
Ahead Therapeutics SL
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Amneal Pharmaceuticals Inc
Amplo Biotechnology Inc
AnTolRx Inc
Argenx SE
Beijing Mabworks Biotech Co Ltd
BioMarin Pharmaceutical Inc
BioXpress Therapeutics SA
Cabaletta Bio Inc
Cartesian Therapeutics Inc
Chord Therapeutics Sarl
Chugai Pharmaceutical Co Ltd
Cour Pharmaceuticals Development Co Inc
CSL Ltd
CuraVac Inc
Cytodyn Inc
DAS Therapeutics Inc
HanAll Biopharma Co Ltd
Horizon Therapeutics Plc
ImmunAbs Inc
Johnson & Johnson
KIMS Pharmaceutical Co Ltd
Kiniksa Pharmaceuticals Ltd
Medytox Inc
MetVital Inc
NeoProgen Inc
Neurotune AG
Nihon Pharmaceuticals Co Ltd
NMD Pharma AS
Novartis AG
Oak Hill Bio Inc
Pfizer Inc
PlateletBio
Principia Biopharma Inc
Protalex Inc
Ra Pharmaceuticals Inc
Rallybio Corp
ReceptoPharm Inc
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Takeda Pharmaceutical Co Ltd
Tasly Biopharmaceuticals Co Ltd
Taxon Therapeutics Ltd
Toleranzia AB
UCB SA
Yantai Rongchang Pharmaceutical Co Ltd
Myasthenia Gravis - Drug Profiles
(ondansetron + pyridostigmine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACT-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ALXN-2050 - Drug Profile
Product Description
Mechanism Of Action
History of Events
amifampridine phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
AMP-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Anhydrous enol oxaloacetate - Drug Profile
Product Description
Mechanism Of Action
AT-1616 - Drug Profile
Product Description
Mechanism Of Action
B-20672 - Drug Profile
Product Description
Mechanism Of Action
batoclimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
cladribine - Drug Profile
Product Description
Mechanism Of Action
CSL-730 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVMG-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Descartes-08 - Drug Profile
Product Description
Mechanism Of Action
History of Events
eculizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
gefurulimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target MuSK for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene-Modified Cell Therapy for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
IM-101 - Drug Profile
Product Description
Mechanism Of Action
inebilizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
iscalimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
K-127 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KIMS-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KPL-404 - Drug Profile
Product Description
Mechanism Of Action
History of Events
leronlimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
methotrexate - Drug Profile
Product Description
Mechanism Of Action
History of Events
mezagitamab - Drug Profile
Product Description
Mechanism Of Action
History of Events
MIL-62 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MT-927 - Drug Profile
Product Description
Mechanism Of Action
nipocalimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
NMDP-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
nomacopan - Drug Profile
Product Description
Mechanism Of Action
History of Events
NPO-15 - Drug Profile
Product Description
Mechanism Of Action
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
OHB-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
orilanolimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
PF-06755347 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pozelimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Protein for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
PRTX-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ravulizumab LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
rituximab biosimilar 1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RLYB-116 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rozanolixizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
RPI-78M - Drug Profile
Product Description
Mechanism Of Action
satralizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Cardiovascular Disease, Acute Renal Failure (ARF) (Acute Kidney Injury), Alzheimer's Disease and Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
telitacicept - Drug Profile
Product Description
Mechanism Of Action
History of Events
TOL-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
tolebrutinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
zilucoplan - Drug Profile
Product Description
Mechanism Of Action
History of Events
zilucoplan XR - Drug Profile
Product Description
Mechanism Of Action
History of Events
Myasthenia Gravis - Dormant Projects
Myasthenia Gravis - Discontinued Products
Myasthenia Gravis - Product Development Milestones
Featured News & Press Releases
Mar 01, 2022: U.S. Food and Drug Administration grants Cabaletta Bio fast track designation for MuSK-CAART
Feb 14, 2022: Argenx's Vyvgart offers a substantial advance over other treatments for generalized myasthenia gravis, spherix survey suggests
Feb 04, 2022: UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
Jan 24, 2022: Soleo Health selected as limited distribution partner for VYVGART
Jan 20, 2022: argenx announces VYVGART approval in Japan for the treatment of generalized myasthenia gravis
Jan 03, 2022: More than two decades of UTSW research paves way for first-in-kind drug
Dec 31, 2021: Hanall Biopharma’s partner Immunovant to start phase 3 clinical trial for myasthenia gravis in the first half of next year
Dec 30, 2021: Immunovant provides regulatory update regarding initiation of phase 3 trial for batoclimab in Myasthenia Gravis in the first half of 2022
Dec 21, 2021: Submission based on positive phase III trial in which Ultomiris significantly improved functional activities as measured by myasthenia gravis-activities of daily living profile
Dec 17, 2021: Zai Lab partner argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART (efgartigimod alfa-fcab) in generalized myasthenia gravis
Dec 14, 2021: RemeGen reiterates commitment to its battle against autoimmune disease on World Strengthened Immunity Day 2021
Dec 10, 2021: UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis
Nov 11, 2021: Start of Toleranzia’s planned clinical trial with TOL2 postponed due to global shortage of certain materials for production of the drug substance
Oct 19, 2021: Harbour BioMed announces dosing of first patient of batoclimab phase II trial in patients with thyroid eye disease
Oct 08, 2021: argenx to highlight potential first-in-class FcRn antagonist Efgartigimod at upcoming Neuromuscular Meetings
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Myasthenia Gravis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Myasthenia Gravis - Pipeline by Ahead Therapeutics SL, 2022
Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, 2022
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, 2022
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, 2022
Myasthenia Gravis - Pipeline by Amneal Pharmaceuticals Inc, 2022
Myasthenia Gravis - Pipeline by Amplo Biotechnology Inc, 2022
Myasthenia Gravis - Pipeline by AnTolRx Inc, 2022
Myasthenia Gravis - Pipeline by Argenx SE, 2022
Myasthenia Gravis - Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, 2022
Myasthenia Gravis - Pipeline by BioXpress Therapeutics SA, 2022
Myasthenia Gravis - Pipeline by Cabaletta Bio Inc, 2022
Myasthenia Gravis - Pipeline by Cartesian Therapeutics Inc, 2022
Myasthenia Gravis - Pipeline by Chord Therapeutics Sarl, 2022
Myasthenia Gravis - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Myasthenia Gravis - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022
Myasthenia Gravis - Pipeline by CSL Ltd, 2022
Myasthenia Gravis - Pipeline by CuraVac Inc, 2022
Myasthenia Gravis - Pipeline by Cytodyn Inc, 2022
Myasthenia Gravis - Pipeline by DAS Therapeutics Inc, 2022
Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, 2022
Myasthenia Gravis - Pipeline by Horizon Therapeutics Plc, 2022
Myasthenia Gravis - Pipeline by ImmunAbs Inc, 2022
Myasthenia Gravis - Pipeline by Johnson & Johnson, 2022
Myasthenia Gravis - Pipeline by KIMS Pharmaceutical Co Ltd, 2022
Myasthenia Gravis - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
Myasthenia Gravis - Pipeline by Medytox Inc, 2022
Myasthenia Gravis - Pipeline by MetVital Inc, 2022
Myasthenia Gravis - Pipeline by NeoProgen Inc, 2022
Myasthenia Gravis - Pipeline by Neurotune AG, 2022
Myasthenia Gravis - Pipeline by Nihon Pharmaceuticals Co Ltd, 2022
Myasthenia Gravis - Pipeline by NMD Pharma AS, 2022
Myasthenia Gravis - Pipeline by Novartis AG, 2022
Myasthenia Gravis - Pipeline by Oak Hill Bio Inc, 2022
Myasthenia Gravis - Pipeline by Pfizer Inc, 2022
Myasthenia Gravis - Pipeline by PlateletBio, 2022
Myasthenia Gravis - Pipeline by Principia Biopharma Inc, 2022
Myasthenia Gravis - Pipeline by Protalex Inc, 2022
Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, 2022
Myasthenia Gravis - Pipeline by Rallybio Corp, 2022
Myasthenia Gravis - Pipeline by ReceptoPharm Inc, 2022
Myasthenia Gravis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Myasthenia Gravis - Pipeline by Samsung Bioepis Co Ltd, 2022
Myasthenia Gravis - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Myasthenia Gravis - Pipeline by Tasly Biopharmaceuticals Co Ltd, 2022
Myasthenia Gravis - Pipeline by Taxon Therapeutics Ltd, 2022
Myasthenia Gravis - Pipeline by Toleranzia AB, 2022
Myasthenia Gravis - Pipeline by UCB SA, 2022
Myasthenia Gravis - Pipeline by Yantai Rongchang Pharmaceutical Co Ltd, 2022
Myasthenia Gravis - Dormant Projects, 2022
Myasthenia Gravis - Dormant Projects, 2022 (Contd..1)
Myasthenia Gravis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Myasthenia Gravis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
